481 related articles for article (PubMed ID: 25387054)
1. AA amyloidosis: pathogenesis and targeted therapy.
Westermark GT; Fändrich M; Westermark P
Annu Rev Pathol; 2015; 10():321-44. PubMed ID: 25387054
[TBL] [Abstract][Full Text] [Related]
2. Transmission of systemic AA amyloidosis in animals.
Murakami T; Ishiguro N; Higuchi K
Vet Pathol; 2014 Mar; 51(2):363-71. PubMed ID: 24280941
[TBL] [Abstract][Full Text] [Related]
3. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils.
Johan K; Westermark G; Engström U; Gustavsson A; Hultman P; Westermark P
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2558-63. PubMed ID: 9482925
[TBL] [Abstract][Full Text] [Related]
4. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.
Jayaraman S; Gantz DL; Haupt C; Gursky O
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6507-E6515. PubMed ID: 28743750
[TBL] [Abstract][Full Text] [Related]
5. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
6. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Kumon Y; Hirata S; Takaoka H
Clin Exp Rheumatol; 2014; 32(4):501-8. PubMed ID: 24959698
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis and biochemistry of amyloidosis.
Cohen AS; Connors LH
J Pathol; 1987 Jan; 151(1):1-10. PubMed ID: 3550020
[TBL] [Abstract][Full Text] [Related]
8. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.
Bansal A; Schmidt M; Rennegarbe M; Haupt C; Liberta F; Stecher S; Puscalau-Girtu I; Biedermann A; Fändrich M
Nat Commun; 2021 Feb; 12(1):1013. PubMed ID: 33579941
[TBL] [Abstract][Full Text] [Related]
9. Signs of cross-seeding: aortic medin amyloid as a trigger for protein AA deposition.
Larsson A; Malmström S; Westermark P
Amyloid; 2011 Dec; 18(4):229-34. PubMed ID: 22070546
[TBL] [Abstract][Full Text] [Related]
10. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism.
Lundmark K; Westermark GT; Olsén A; Westermark P
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6098-102. PubMed ID: 15829582
[TBL] [Abstract][Full Text] [Related]
11. Extrahepatic production of acute phase serum amyloid A.
Upragarin N; Landman WJ; Gaastra W; Gruys E
Histol Histopathol; 2005 Oct; 20(4):1295-307. PubMed ID: 16136510
[TBL] [Abstract][Full Text] [Related]
12. Recent insights into the pathogenesis of type AA amyloidosis.
van der Hilst JC
ScientificWorldJournal; 2011 Mar; 11():641-50. PubMed ID: 21403980
[TBL] [Abstract][Full Text] [Related]
13. Animal models for reactive amyloidosis.
Gruys E; Snel FW
Baillieres Clin Rheumatol; 1994 Aug; 8(3):599-611. PubMed ID: 7954864
[TBL] [Abstract][Full Text] [Related]
14. Review. Reflections on amyloidosis in Papua New Guinea.
Westermark P; Westermark GT
Philos Trans R Soc Lond B Biol Sci; 2008 Nov; 363(1510):3701-5. PubMed ID: 18849285
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of amyloid proteins.
Benson MD; Kluve-Beckerman B; Liepnieks JJ; Murrell JR; Hanes D; Uemichi T
Ciba Found Symp; 1996; 199():104-13; discussion 113-8. PubMed ID: 8915606
[TBL] [Abstract][Full Text] [Related]
16. Deposition, Clearance, and Reinduction of Amyloid A Amyloid in Interleukin 1 Receptor Antagonist Knockout Mice.
Watanabe K; Uchida K; Chambers JK; Ushio N; Nakayama H
Vet Pathol; 2017 Jan; 54(1):99-110. PubMed ID: 27565681
[TBL] [Abstract][Full Text] [Related]
17. Aggregation of Mouse Serum Amyloid A Protein Was Promoted by Amyloid-Enhancing Factors with the More Genetically Homologous Serum Amyloid A.
Lin X; Watanabe K; Kuragano M; Tokuraku K
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494290
[TBL] [Abstract][Full Text] [Related]
18. [A review for recent advances in AA amyloid research and therapeutic approach to AA amyloidosis complicating rheumatoid arthritis].
Tamura H; Hasegawa K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):35-42. PubMed ID: 19252376
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
20. Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties.
Takase H; Tanaka M; Miyagawa S; Yamada T; Mukai T
Biochem Biophys Res Commun; 2014 Jan; 444(1):92-7. PubMed ID: 24440699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
